Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Vimizim

Chemical Nameelosulfase alfa
Dosage FormInjection (intravenous; 5 mg/5 mL (1 mg/mL))
Drug ClassEnzymes
SystemMusculoskeletal
CompanyBioMarin
Approval Year2014

Indication

  • Treatment for Mucopolysaccharidosis type IVA (Morquio A syndrome).
Last updated on 7/18/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vimizim (elosulfase alfa) Prescribing Information.2019BioMarin Pharmaceutical Inc., Novato, CA
Document TitleYearSource
Elosulfase alfa for treating mucopolysaccharidosis type 4A. 2022NICE
Document TitleYearSource
Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance.2019Orphanet Journal of Rare Diseases